🇺🇸 FDA
Pipeline program

AdV-tk

BrTK01

Phase 1 mab completed

Quick answer

AdV-tk for Malignant Glioma is a Phase 1 program (mab) at Candel Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Candel Therapeutics
Indication
Malignant Glioma
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials